TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <100nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: 300nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <100nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <100nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <100nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <100nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <100nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <250nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <250nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <250nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <250nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <250nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <250nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <250nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <500nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <500nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <1.00E+3nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <1.00E+3nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <1.00E+3nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <1.00E+3nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <1.00E+3nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <100nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: >2.00E+3nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute
US Patent
The Scripps Research Institute
US Patent
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair